| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | DERMAXON LLC | 6610 JUSTIN CT | MISSOULA | MT | 59803-2969 | MISSOULA | USA | R43AR083781 | Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne. | 000 | 1 | NIH | 10/31/2023 | $0 |
| | 2024 | 2021 | DERMAXON LLC | 6610 JUSTIN CT | MISSOULA | MT | 59803-2969 | MISSOULA | USA | R41TR003929 | Novel therapeutic target to combat cutaneous lupus | 000 | 1 | NIH | 1/10/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $295,423 ) |
| | 2023 | 2023 | DERMAXON LLC | 6610 JUSTIN CT | MISSOULA | MT | 59803-2969 | MISSOULA | USA | R43AR083781 | Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne. | 000 | 1 | NIH | 9/20/2023 | $295,423 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2019 | DERMAXON LLC | 6610 JUSTIN CT | MISSOULA | MT | 59803-2969 | MISSOULA | USA | R44AR069416 | Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis | 000 | 3 | NIH | 12/7/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $298,132 ) |
| | 2021 | 2021 | DERMAXON LLC | 6610 JUSTIN CT | MISSOULA | MT | 59803-2969 | MISSOULA | USA | R41TR003929 | Novel therapeutic target to combat cutaneous lupus | 000 | 1 | NIH | 3/25/2021 | $298,132 |
| | 2021 | 2019 | DERMAXON LLC | 6610 JUSTIN CT | MISSOULA | MT | 59803-2969 | MISSOULA | USA | R43AR076842 | Topical selective T-type blockers for the treatment of pruritus | 000 | 1 | NIH | 7/26/2021 | $0 |
| | 2021 | 2018 | DERMAXON LLC | 6610 JUSTIN CT | MISSOULA | MT | 59803-2969 | MISSOULA | USA | R41NS105304 | Topical selective T-type blockers for the treatment of neuropathic pain | 000 | 1 | NIH | 12/8/2020 | $0 |
| | 2021 | 2016 | DERMAXON LLC | 6610 JUSTIN CT | MISSOULA | MT | 59803-2969 | MISSOULA | USA | R41AR069416 | Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis | 000 | 1 | NIH | 8/6/2021 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,188,838 ) |
| | 2019 | 2019 | DERMAXON LLC | 6610 JUSTIN CT | MISSOULA | MT | 59803-2969 | MISSOULA | USA | R43AR076842 | Topical selective T-type blockers for the treatment of pruritus | 000 | 1 | NIH | 8/29/2019 | $224,999 |
| | 2019 | 2019 | DERMAXON LLC | 6610 JUSTIN CT | MISSOULA | MT | 59803-2969 | MISSOULA | USA | R44AR069416 | Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis | 000 | 2 | NIH | 2/28/2019 | $26,586 |
| | 2019 | 2019 | DERMAXON LLC | 6610 JUSTIN CT | MISSOULA | MT | 59803-2969 | MISSOULA | USA | R44AR069416 | Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis | 001 | 3 | NIH | 7/18/2019 | $937,253 |
|
| Issue Date FY: 2018 ( Subtotal = $764,508 ) |
| | 2018 | 2018 | DERMAXON LLC | 6610 JUSTIN CT | MISSOULA | MT | 59803-2969 | MISSOULA | USA | R44AR069416 | Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis | 000 | 2 | NIH | 9/24/2018 | $536,029 |
| | 2018 | 2018 | DERMAXON LLC | 6610 JUSTIN CT | MISSOULA | MT | 59803-2969 | MISSOULA | USA | R44AR069416 | Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis | 001 | 2 | NIH | 9/26/2018 | $0 |
| | 2018 | 2018 | DERMAXON LLC | 6610 JUSTIN CT | MISSOULA | MT | 59803-2969 | MISSOULA | USA | R41NS105304 | Topical selective T-type blockers for the treatment of neuropathic pain | 000 | 1 | NIH | 5/4/2018 | $228,479 |
|
| Issue Date FY: 2016 ( Subtotal = $215,640 ) |
| | 2016 | 2016 | DERMAXON LLC | 6610 JUSTIN COURT | MISSOULA | MT | 59803 | MISSOULA | USA | R41AR069416 | Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis | 000 | 1 | NIH | 8/25/2016 | $215,640 |
|
| Issue Date FY: 2013 ( Subtotal = $225,000 ) |
| | 2013 | 2013 | DERMAXON LLC | 6610 JUSTIN COURT | MISSOULA | MT | 59803 | MISSOULA | USA | R41AG046987 | INHIBITION OF RETINOIC ACID METABOLISM FOR REVERSAL OF COGNITIVE DEFICITS IN AD | 000 | 1 | NIH | 9/20/2013 | $225,000 |
|
|
